3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Transitional Cell
12
Urinary Bladder Neoplasms
9
Ureteral Neoplasms
4
Urologic Neoplasms
3
Urethral Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Male Urogenital Diseases
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Adenocarcinoma of the Bladder
1
Interventions
Gemcitabine
10
Mitomycin
6
Docetaxel
5
erdafitinib
4
durvalumab
4
BCG Vaccine
4
dodecyl maltoside
3
Cystoscopy
3
ALT-803
2
viscum album peptide
1
tremelimumab
1
pirarubicin
1
monalizumab
1
hydroxycamptothecinum
1
chondroitin sulfate, sodium hyaluronate drug combination
1
Watchful Waiting
1
Transurethral Resection of Bladder
1
Patient Discharge
1
Paclitaxel
1
Mitozytrex
1
Magnetic Resonance Spectroscopy
1
Injections
1
Hyaluronic Acid
1
House Calls
1
Home Care Services
1
Epirubicin
1
Drainage
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Chondroitin Sulfates
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
enfortumab vedotin
×
90 days
×
Clear all
No trials found.